These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 30693648

  • 1. Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage.
    Campanati A, Martina E, Giuliodori K, Bobyr I, Consales V, Offidani A.
    Dermatol Ther; 2019 May; 32(3):e12841. PubMed ID: 30693648
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hidradenitis suppurativa in the pediatric population.
    Liy-Wong C, Pope E, Lara-Corrales I.
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
    [Abstract] [Full Text] [Related]

  • 5. Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
    Grimstad Ø, Kvammen BØ, Swartling C.
    Am J Clin Dermatol; 2020 Oct; 21(5):741-748. PubMed ID: 32761500
    [Abstract] [Full Text] [Related]

  • 6. Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review.
    Ravi M, Trinidad J.
    J Drugs Dermatol; 2022 Apr 01; 21(4):408-412. PubMed ID: 35389587
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A, Takahashi H, Ozawa K, Imafuku S, Nakama T, Takahashi K, Matsuyama T, Okubo Y, Kitamura S, Matsuda N, Zhao Y, Yokoyama M, Hayashi N, Terui T.
    J Dermatol; 2019 Sep 01; 46(9):745-751. PubMed ID: 31282051
    [Abstract] [Full Text] [Related]

  • 11. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T.
    Rev Endocr Metab Disord; 2016 Sep 01; 17(3):343-351. PubMed ID: 26831295
    [Abstract] [Full Text] [Related]

  • 12. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
    Theut Riis P, Thorlacius LR, Jemec GB.
    Expert Opin Investig Drugs; 2018 Jan 01; 27(1):43-53. PubMed ID: 29188733
    [Abstract] [Full Text] [Related]

  • 13. Pain management in patients with hidradenitis suppurativa.
    Horváth B, Janse IC, Sibbald GR.
    J Am Acad Dermatol; 2015 Nov 01; 73(5 Suppl 1):S47-51. PubMed ID: 26470616
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
    Scheinfeld N.
    Dermatol Online J; 2013 Apr 15; 19(4):1. PubMed ID: 24021361
    [Abstract] [Full Text] [Related]

  • 17. The pharmacology of antibiotic therapy in hidradenitis suppurativa.
    Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, Fabbrocini G.
    Expert Rev Clin Pharmacol; 2020 May 15; 13(5):521-530. PubMed ID: 32364806
    [Abstract] [Full Text] [Related]

  • 18. [Hidradenitis suppurativa/acne inversa: An update].
    Kirschke J, Hessam S, Bechara FG.
    Hautarzt; 2015 Jun 15; 66(6):413-22. PubMed ID: 25877488
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS, Hawatmeh FZ, Wong A, Kerdel FA.
    Expert Opin Emerg Drugs; 2020 Sep 15; 25(3):201-211. PubMed ID: 32667213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.